The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
Subscribe To Our Newsletter & Stay Updated
